Skip to main content

Rigel Pharmaceuticals, Inc.

corporate_fare Company Profile

Rigel Pharmaceuticals, Inc.

RIGL·NASDAQ·Life Sciences·CIK 0001034842

This biotechnology company develops and provides new therapies for patients with blood disorders and cancer, focusing on products that target critical disease mechanisms. Its first FDA-approved product is TAVALISSE® (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor. TAVALISSE is approved for adult patients with chronic immune thrombocytopenia (ITP) who have not responded sufficiently to previous treatments. It is also available in Europe and the United Kingdom as TAVLESSE, and in Japan, the Republic of Korea, Canada, and Israel as TAVALISSE for chronic ITP in adults. The company's second FDA-approved product is REZLIDHIA® (olutasidenib), indicated for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test. The company in-licensed REZLIDHIA from Forma Therapeutics, Inc., now Novo Nordisk, in July 2022, securing exclusive worldwide rights for its development, manufacturing, and commercialization. GAVRETO® (pralsetinib) is the company's third FDA-approved product, commercialized starting June 2024. GAVRETO is a once-daily, small molecule, oral kinase inhibitor targeting wild-type rearranged during transfection (RET) and oncogenic RET fusions. It is FDA-approved for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory. The company acquired the US rights for GAVRETO from Blueprint Medicines Corporation, now a Sanofi SA company, in February 2024.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for RIGL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for RIGL spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Rigel Q3 EPS Misses at $0.65 as Launch Costs Weigh, Revenue Tops Estimates
  • Rigel Q3 Revenue Rises to $80.9M on VEPPANU Launch; Net Income Falls to $13.2M
  • Rigel Reports Strong Q2 with $67M Net Product Sales, Raises 2026 Revenue Guidance to $285-$295M
  • Rigel Posts Record Q2 Product Sales, Raises 2026 Revenue Outlook to $295M
  • Rigel Pharmaceuticals Appoints New Chief Medical Officer, Former CMO Departs

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$294.28M
Net Income
$367.02M
Diluted EPS
$19.48
Op. Cash Flow
$75.66M
Gross Profit
$274.66M
Operating Income
$125.47M
Cash & Equivalents
$40.58M
Debt / Equity
0.00×
Net Margin
124.7%
Shares Outstanding
18.31M sh
Source: 10-K · filed 2026-03-03 · accession 0001034842-26-000015

Short Interest & Short Volume

12.93 days to cover

FINRA reported short interest of 2,535,665 shares in RIGL as of the October 30, 2026 settlement, a 7.2% decrease from the prior period — about 12.9 days to cover at its recent average daily volume. On November 20, 2026, 46.4% of RIGL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,535,665 shares as of October 30, 2026
Change vs prior period▼ 7.2%
Days to cover12.93 at avg daily volume of 196,113
Daily short volume (FINRA facilities)46.4% of 125,051 shares on November 20, 2026
5-day average short volume46.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with R →
$40 -0.22% today
52-week range · as of 2026-11-05 $24.95 – $52.6
Market cap
$754.89M
Volume
352.2K (1.4× avg)
3-mo avg 246.6K
Live data · 2026-11-22 12:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RIGL - Latest Insights

RIGL
Nov 05, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $43.90
Real-time Price: $40.00 info
Change: -$3.90 (-9%) info
Market Cap: $754.894M info
RIGL
Nov 05, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.00
Real-time Price: $40.00 info
Change: -$4.00 (-9%) info
Market Cap: $754.894M info
RIGL
Aug 04, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.20
Real-time Price: $40.00 info
Change: -$1.20 (-3%) info
Market Cap: $754.894M info
RIGL
Aug 04, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $39.84
Real-time Price: $40.00 info
Change: +$0.160 (+0.40%) info
Market Cap: $754.894M info
RIGL
Jul 01, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.29
Real-time Price: $40.00 info
Change: +$1.71 (+4%) info
Market Cap: $754.894M info
RIGL
Jun 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $33.37
Real-time Price: $40.00 info
Change: +$6.63 (+20%) info
Market Cap: $754.894M info
RIGL
May 20, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.82
Real-time Price: $40.00 info
Change: +$11.18 (+39%) info
Market Cap: $754.894M info
RIGL
May 12, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $30.31
Real-time Price: $40.00 info
Change: +$9.69 (+32%) info
Market Cap: $754.894M info
RIGL
May 12, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $30.31
Real-time Price: $40.00 info
Change: +$9.69 (+32%) info
Market Cap: $754.894M info
RIGL
May 05, 2026, 4:08 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $25.90
Real-time Price: $40.00 info
Change: +$14.10 (+54%) info
Market Cap: $754.894M info
RIGL
May 05, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.47
Real-time Price: $40.00 info
Change: +$12.53 (+46%) info
Market Cap: $754.894M info
RIGL
May 05, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $27.35
Real-time Price: $40.00 info
Change: +$12.65 (+46%) info
Market Cap: $754.894M info
RIGL
Apr 21, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.00
Real-time Price: $40.00 info
Change: +$9.00 (+29%) info
Market Cap: $754.894M info
RIGL
Apr 03, 2026, 4:02 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $27.53
Real-time Price: $40.00 info
Change: +$12.47 (+45%) info
Market Cap: $754.894M info
RIGL
Apr 03, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $27.53
Real-time Price: $40.00 info
Change: +$12.47 (+45%) info
Market Cap: $754.894M info
RIGL
Jan 12, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $41.40
Real-time Price: $40.00 info
Change: -$1.40 (-3%) info
Market Cap: $754.894M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets